07.24.17
Headquarters: New Brunswick, NJ
twitter.com/JNJComm
www.jnj.com
Headcount: 127,000
Year Established: 1887
Revenues: $71,890 (+3%)
Pharma Revenues: $33,464 (+7%)
Net Income: $16,540 (+7%)
R&D: $9,095 (+1%)
TOP SELLING DRUGS
Drug | Indication | 2016 Sales | (+/-%) |
Remicade | rheumatoid arthritis | $6,966 | 6% |
Stelara | psoriasis | $3,232 | 31% |
Xarelto | deep vein thrombosis, pulmonary embolism | $2,288 | 23% |
Zytiga | prostate cancer | $2,260 | 1% |
Invega Sustenna | schizophrenia | $2,214 | 21% |
Prezista | HIV/AIDS | $1,851 | 2% |
Simponi | rheumatoid arthritis | $1,745 | 31% |
Invokana | type 2 diabetes | $1,407 | 7% |
Imbruvica | oncology | $1,251 | 82% |
Velcade | velcade, mantle cell lymphoma | $1,224 | -8% |
Headquartered in New Brunswick, NJ, Johnson & Johnson (J&J) operates in more than 60 countries while its pharmaceutical and healthcare products are supplied to over 200 countries. The Pharmaceutical segment contributes nearly 47% of J&J’s total revenues. The segment reported 2016 revenues of $33.5 billion—a 7% increase over 2015—and comprises several franchises: Immunology, Infectious Disease, Neuroscience, Oncology, and Cardiovascular and Metabolics. The major blockbuster drugs under the Immunology franchise are Remicade, Stelara, and Simponi/Simponi Aria. The franchise revenues reported growth of 7% to $12 billion in 2016.
Cancer collaborations
J&J’s Oncology franchise grew 24% to $6 billion during 2016, driven by increased sales of Imbruvica and a strong uptake of Darzalex. During the year Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, entered several cancer collaborations. First it teamed up with Tesaro for exclusive rights to the investigational compound niraparib in prostate cancer. Niraparib is an orally administered, once daily, potent, and highly selective poly polymerase (PARP) inhibitor, currently in late-stage development for patients with metastatic breast cancer and ovarian cancer. Janssen will develop and commercialize niraparib for patients with prostate cancer worldwide, except in Japan. Tesaro received an upfront payment of $35 million, and is eligible to receive additional milestone payments of up to $415 million.
With Bristol-Myers Squibb (BMS), Janssen entered a clinical research collaboration to evaluate BMS’ immuno-oncology drug Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer (NSCLC). Opdivo is a human antibody designed to alleviate immune suppression. JNJ-64041757 is designed to induce an immune response against NSCLC tumors.
Later in the year, Janssen entered into a master clinical trial collaboration and supply agreement with Onyx Pharmaceuticals, a subsidiary of Amgen, to evaluate the efficacy and safety of CD38-directed immunotherapy daratumumab (DARZALEX) in combination with a proteasome inhibitor (PI) carfilzomib (KYPROLIS) and dexamethasone. The agreement covers all potential opportunities for combining daratumumab and carfilzomib to treat cancer. Janssen licensed daratumumab from Genmab and is responsible for all global development, marketing and manufacturing. Carfilzomib is developed and commercialized by Amgen.
Industrial bioscience company Amyris entered into a research agreement with Janssen facilitated by Johnson & Johnson Innovation. The collaboration will use Amyris’s µPharm platform technology to develop a customized library of natural and natural-like compounds to test against Janssen’s therapeutic target. Amyris’s µPharm platform technology enables an integrated discovery and production process for therapeutic compounds. It provides access to scarce natural compounds and also creates new diversity based on natural compound scaffolds.
Janssen Biotech also licensed Ionis Pharmaceuticals’ IONIS-JBI1-2.5Rx, an oral antisense drug for the treatment of a GI autoimmune disease, for $10 million. Janssen assumes all global development, regulatory and commercialization responsibilities after Ionis completes the IND-enabling studies. Ionis is eligible to receive as much as $800 million in development, regulatory and sales milestones and license fees for three programs, as well as royalties on sales from any product that is successfully commercialized.
Janssen Pharmaceutica NV divested five anesthesia and pain management injectable products to Piramal Enterprises’ wholly owned Critical Care subsidiary in the UK for $155 million. The products include five injectable versions of Janssen’s Sublimaze (fentanyl citrate), Sufenta (sufentanil citrate), Rapifen (alfentanil hydrochloride), Dipidolor (piritramide), and Hypnomidate (etomidate), which are currently marketed in more than 50 countries. Piramal acquired the brand names and related IP, including how to make both the API and the finished dosage forms of the products. The acquisition does not include the transfer of any manufacturing facilities or employees.
Janssen will continue to supply finished dosage forms for up to three years and API for up to five years, and will continue to sell the products on behalf of Piramal until the marketing authorizations or relevant business relations are transferred to Piramal.